Journal · Updated 2026-08-11
Tennessee Medicaid and GLP-1s in 2026: Covered on Every Count — With the Drug List Still to Confirm
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
Tennessee covers GLP-1 medications for weight loss under Medicaid, with prior authorization — TennCare appears on KFF's January 2026 count of thirteen covering states, the April tracker verification, and the July count of roughly eleven. The honest asterisk comes straight from the tracker record: Tennessee's row carries a verify-the-specific-drugs flag, meaning the covered status is multiply confirmed but the exact formulary list — all three of Wegovy, Zepbound, and Saxenda, or a subset, and which is preferred — needs confirmation against the current TennCare preferred drug list or your managed-care plan's formulary. This page reports exactly that shape: solid status, one open detail, and the single call that closes it.
The one call, scripted
TennCare runs through managed-care organizations, so the operative formulary is usually your plan's. The call — your plan's pharmacy line, or TennCare pharmacy services — asks three things in order: which GLP-1 products are covered for the weight-management indication and which is preferred; what the prior authorization requires (BMI threshold, comorbidity documentation, step therapy through non-GLP-1 agents, lifestyle-program evidence); and how renewals work — whether a documented-weight-loss rule of the kind Virginia prints governs continuation. Write down the answers, the representative's name, and the date; the PA guide converts them into a first-submission package, and a reader who sends the current criteria document to the corrections desk upgrades this page to primary-sourced.
The standing structure, Tennessee edition
The full map applies: the federally required diabetes door (Ozempic, Mounjaro); the cardiovascular, sleep-apnea, kidney, and MASH doors that federal rebate-program rules generally require with PA, mapped in the indication-door playbook; the under-21 EPSDT path; and the cash floor — compounded semaglutide near one hundred dollars a month, tirzepatide under one hundred seventy on current promotional cards — with the verification homework attached for anyone the criteria exclude. No 2026 Tennessee restriction event appears on the change ledger; the annual re-check habit applies here as in every covering state. National context at the Medicaid hub.
Questions people ask
Does TennCare cover Wegovy or Zepbound for weight loss in 2026?
Tennessee is verified as a covering state with prior authorization on every major 2026 count. The tracker record flags the specific drug list for confirmation, so verify which GLP-1 products your TennCare managed-care plan's formulary covers — and which is preferred — before your prescriber submits.
What does TennCare's prior authorization require?
PA is verified as required; Tennessee-specific thresholds are not published in our sources. Expect the standard covering-state package — BMI documentation, comorbidities where applicable, step therapy, lifestyle evidence — and get the current criteria from your plan's pharmacy line rather than any summary, including this one.
Is Tennessee's coverage stable?
No restriction event or pending prohibition appears in our 2026 sources for Tennessee — a clean row, like Delaware's. The same caveat applies: most 2026 cuts arrived through annual budget bills, so the annual re-check is the habit that catches changes early.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.